

available at www.sciencedirect.com

ScienceDirect

www.elsevier.com/locate/molonc

***TP53* mutation-correlated genes predict the risk of tumor relapse and identify *MPS1* as a potential therapeutic kinase in *TP53*-mutated breast cancers**



Balázs Györffy^{a,b}, Giulia Bottai^c, Jacqueline Lehmann-Che^d, György Kéri^{e,f},
László Örfi^{f,g}, Takayuki Iwamoto^h, Christine Desmedtⁱ,
Giampaolo Bianchini^j, Nicholas C. Turner^k, Hugues de Thè^d, Fabrice André^l,
Christos Sotiriou^l, Gabriel N. Hortobagyi^m, Angelo Di Leoⁿ, Lajos Pusztai^o,
Liberio Santarpia^{c,*,1}

^aResearch Laboratory of Pediatrics and Nephrology, Hungarian Academy of Sciences, Budapest, Hungary

^bOncogenomic Research Group, 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary

^cTranslational Research Unit, Department of Oncology, Istituto Toscano Tumori, Piazza dell'Ospedale 2, Prato 59100, Italy

^dDepartment of Biochemistry and INSERM U944, University Rene Diderot, Paris 7, Saint Louis Hospital, Assistance Publique Hôpitaux de Paris, Paris, France

^ePathobiochemistry Research Group of Hungarian Academy of Sciences, Semmelweis University, Department of Medicinal Chemistry, 1444, Bp. 8, POB 260, Hungary

^fVichem Chemie Research Ltd, 1022, Herman Otto 15, Budapest, Hungary

^gDepartment of Pharmaceutical Chemistry, Semmelweis University, Budapest, Hungary

^hDepartment of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan

ⁱBreast Cancer Translational Laboratory, Université Libre de Bruxelles, Jules Bordet Institute, Brussels, Belgium

^jDivision of Medical Oncology, San Raffaele – Scientific Institute, Milan, Italy

^kThe Breakthrough Breast Cancer Research Center, Institute of Cancer Research, London, UK

^lDepartment of Medical Oncology, Institut National de la Santé et de la Recherche Médicale Unit U981, Institut Gustave Roussy, Villejuif, France

^mBreast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

ⁿMedical Oncology Unit Sandro Pitigliani, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy

^oYale Cancer Center, New Haven, CT, USA

ARTICLE INFO

Article history:

Received 18 December 2013

Accepted 29 December 2013

Available online 5 January 2014

Keywords:

Breast cancer subtypes

TP53 mutation status

Tumor relapse

ABSTRACT

Breast cancers (BC) carry a complex set of gene mutations that can influence their gene expression and clinical behavior. We aimed to identify genes driven by the *TP53* mutation status and assess their clinical relevance in estrogen receptor (ER)-positive and ER-negative BC, and their potential as targets for patients with *TP53* mutated tumors. Separate ROC analyses of each gene expression according to *TP53* mutation status were performed. The prognostic value of genes with the highest AUC were assessed in a large dataset of untreated, and neoadjuvant chemotherapy treated patients. The mitotic checkpoint gene *MPS1* was the most significant gene correlated with *TP53* status, and the most significant prognostic marker in all ER-positive BC datasets. *MPS1* retained its prognostic value independently from the

* Corresponding author. Tel.: +39 0574 434471; fax: +39 0574 435176.

E-mail addresses: liberosantarpia@yahoo.it, libero.santarpia@humanitasresearch.it (L. Santarpia).

¹ Current address: Oncology Experimental Therapeutics Unit, IRCCS – Humanitas Clinical and Research Center, Milan, Italy.
1574-7891/\$ – see front matter © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
<http://dx.doi.org/10.1016/j.molonc.2013.12.018>

MPS1 protein kinase
SP600125
Chemotherapy

type of treatment administered. The biological functions of MPS1 were investigated in different BC cell lines. We also assessed the effects of a potent small molecule inhibitor of MPS1, SP600125, alone and in combination with chemotherapy. Consistent with the gene expression profiling and siRNA assays, the inhibition of MPS1 by SP600125 led to a reduction in cell viability and a significant increase in cell death, selectively in TP53-mutated BC cells. Furthermore, the chemical inhibition of MPS1 sensitized BC cells to conventional chemotherapy, particularly taxanes. Our results collectively demonstrate that TP53-correlated kinase MPS1, is a potential therapeutic target in BC patients with TP53 mutated tumors, and that SP600125 warrant further development in future clinical trials.

© 2014 Federation of European Biochemical Societies.

Published by Elsevier B.V. All rights reserved.

1. Introduction

Breast cancer (BC) is a heterogeneous disease comprising different molecular subtypes characterized by different types of genetic alterations ([Cancer Genome Atlas Network, 2012](#); [Santarpia et al., 2012](#); [Sotiriou and Pusztai, 2009](#)). Activation of distinct gene and signaling pathways are associated with prognosis and different responses to therapies ([Iwamoto et al., 2011](#); [Santarpia et al., 2013](#)). The tumor suppressor TP53 is the most frequently altered gene in human cancer, including BC. The importance of TP53 as a tumor suppressor in BC is highlighted also by the occurrence of TP53 mutations in the majority of HER2-positive, and basal-like BC subtypes, and in an important percentage of luminal A and B subtypes ([Cancer Genome Atlas Network, 2012](#)). TP53 mutations in BC have been found associated with earlier onset, increased aggressiveness of tumors, aneuploidy, lack of response to endocrine therapies, and in general with poor prognosis ([Olivier et al., 2006](#)). Few studies have analyzed a limited number of BC samples and identified prognostic gene signatures correlated with TP53 status ([Bonnefoi et al., 2011](#); [Coutant et al., 2011](#); [Miller et al., 2005](#); [Troester et al., 2006](#)). TP53 is an important regulator of several cellular signaling pathways and the disruption of TP53 functions has been associated with the impairment of DNA repair, cell cycle arrest and apoptosis, which ultimately leads to genomic instability and cancer progression ([Turner et al., 2013](#); [Walerych et al., 2012](#)).

Restoring endogenous TP53 function holds a lot of promise, although it is still a challenging task due to the complex signaling and multiple cellular functions of TP53. However, considering the relevant role of TP53 signaling pathway in BC, a potential targeting approach could be through the modulation of TP53-regulated downstream signals. This would be particularly relevant to the tailoring of individual therapies, especially when the treatment agents affect TP53-dependent biological responses.

In this study, we integrated a large cohort of BC patients, constructed a complete database to identify a more robust gene signature of target genes associated with TP53 mutation status ([Gyorffy et al., 2009](#)). Several BC datasets for gene expression data containing TP53 mutation status and clinical informations of patients with long-term follow-up were simultaneously analyzed. We combined different levels of data to identify important genes potentially regulated by mutant TP53 and having clinical relevance. Therefore, we assessed the role of the most relevant gene that arose from

our analysis, the human monopolar spindle 1 MPS1, in TP53-proficient and -deficient BC cell lines. Finally, we used a potent inhibitor of MPS1, SP600125, alone and in combination with chemotherapy, which resulted in reduced proliferation and a significant cell death of BC cells. Moreover, inhibition of MPS1 caused an important chemosensitization of cancer cells.

2. Materials and methods

2.1. Datasets

We structured the collection of public datasets according to the “Preferred Reporting Items for Systematic Reviews and Meta-Analyses” (PRISMA) guidelines ([Moher et al., 2009](#)). The complete workflow of the performed analyses is summarized in [Figure 1](#). We used a similar approach as previously reported ([Coutant et al., 2011](#)) and in a very large cohort of BC patients. To assess the prognostic value of the mutant TP53-related genes, five independent BC datasets containing TP53 mutation status, gene expression and clinical data with follow-up were used as the discovery cohort (estrogen receptor (ER)-positive = 511, and ER-negative = 184) ([Supplementary Table 1](#)) ([Bertheau et al., 2007](#); [Desmedt et al., 2011](#); [Iwamoto et al., 2011](#); [Miller et al., 2005](#); [Reme et al., 2013](#)).

To evaluate the association between mutant TP53-related gene expressions and tumor relapse in BC patients, we tested the expression of selected genes in patients who did not receive any treatment by analyzing three different lymph node negative BC datasets (Mainz GSE11121, Wang GSE2034, and TRANSBIG GSE7390) for a total of 684 patients ([Supplementary Table 1](#)). We also selected the most significant gene that arose from our *in silico* analysis, a specific kinase gene, MPS1 and assessed its prognostic role in BC patients stratified for ER (after correction for HER2) who received different chemotherapy regimens. Specifically, we analyzed six independent cohorts of patients ($n = 528$) who received neo-adjuvant chemotherapy ([Supplementary Table 1](#)) ([Desmedt et al., 2009](#); [Hatzis et al., 2011](#); [Karn et al., 2011](#)).

2.2. Array processing

All arrays were downloaded and normalized in the R environment using the *affy* Bioconductor package as previously described ([Gyorffy and Schafer, 2009](#)). For genes measured by several probe sets, the most reliable probe set was selected using




Figure 1 – General workflow of the study and data processing.

JetSet (Li et al., 2011). Only probe sets reaching a MAS5 expression value of 1000 in at least one of the samples were used in the statistical computations. Additionally, all microarray files were compared using the ranked expression of all genes to spot microarrays re-published in different studies. The ER status was identified as previously described (Gyorffy et al., 2012).

2.3. Statistical analysis

The ROC analysis was performed in the R statistical environment (<http://www.r-project.org>) using the ROC Bioconductor library (<http://www.bioconductor.org>). A Bonferroni correction was applied to account for multiple testing. The statistical significance was set at $p < 0.001$.

The Kaplan–Meier survival analysis was performed as previously described (Gyorffy et al., 2010). The Kaplan–Meier survival plot and Cox regression models were computed in WinStat 2013 (Robert K. Fitch Software, Germany). The functional annotation and pathway analysis was performed using the NCBI DAVID server (Huang et al., 2009a, 2009b) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (Kanehisa and Goto, 2000).

Correlative studies between the most significant mutant TP53-correlated genes and proliferation (MKI67 probe [212021_s_at] expression) were performed on two independent BC datasets (Miller et al., 2005; Iwamoto et al., 2011) by Pearson correlation analysis.

2.4. Cell culture and treatments

The human BC cell lines MCF7, MDA-MB-231 and T47D were obtained from American Type Cell Collection (ATCC). MCF7 and MDA-MB-231 cells were cultured in DMEM medium, and T47D cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. For the experiments, the MCF7, MDA-MB-231 and T47D cells were

grown in phenol red-free culture medium under serum-free conditions. 2H-Dibenzo[cd,g]indazol-6-one (SP600125) was selected as a MPS1 inhibitor from Vichem's Chemical Validation Library (Bennett Brydon L. et al., US Pat. App. Publ., 20040072888, 15 Apr. 2004). SP600125 was synthesized in a one-step cyclization of 1-chloro-anthraquinone with hydrazine hydrate, as previously described (Kim and Wiemer, 2004). SP600125 was solubilized in DMSO and was used at a final concentration of 10 μ M; paclitaxel and doxorubicin were used at concentration of 1 μ M and 4 μ M, respectively. The appropriate amount of DMSO was employed for the negative control condition.

2.5. Western blotting

The cells were harvested and lysed in a RIPA buffer containing protease inhibitors (Sigma–Aldrich). The total protein (30 μ g) was denatured, separated by 4%–20% SDS-PAGE (BioRad) and transferred to Immuno-Blot™ polyvinylidene difluoride (PVDF) membranes (BioRad). After blocking the membranes in 5% non-fat milk powder dissolved in phosphate-buffered saline (PBS), they were incubated overnight in 0.5% non-fat milk powder at 4 °C with primary anti-MPS1 antibody (Millipore). Afterwards, the membranes were incubated for one hour with an HRP-conjugated anti-mouse IgG (Millipore). After washing, a chemiluminescent substrate (Millipore) was added to the membranes, which were then exposed in the Chemidoc XRS station (Biorad). To control for protein loading, membranes were stripped and re-probed with an anti- β actin antibody (Life Technologies). Band intensities were analyzed and calculated using the Quantity One 4.6 software (BioRad).

2.6. Cell viability and proliferation assays

Viable cells were identified using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay (MTT; Sigma). Briefly, cells were plated (3×10^3 cells/well) on 96-well plates

in growth medium supplemented with 10% serum, and SP600125 or DMSO (for control cells) was added 24 h later. Seventy-two hours after the SP600125 treatment, the MTT reagent (5 mg/ml in PBS) was added to each well, followed by incubation for 4 h at 37 °C. The MTT crystals in each well were solubilized in DMSO. The absorbance was read at 560 nm with an iMark plate reader (BioRad). All the treatments were performed in triplicate, and cell viability was expressed as a percentage of the untreated controls (mean \pm S.D.). For proliferation assay, serum starved BC cell lines (approximately 80% density) were treated with SP600125 or DMSO. Cell proliferation was assessed using a commercial kit (cell proliferation enzyme-linked immunosorbent assay, 5-bromo-2'-deoxyuridine (BrdU); Roche Applied Science) according to the manufacturer's instructions. Briefly, after 48 h of incubation with SP600125 or DMSO, the cells were labeled with BrdU for 3 h at 37 °C. The cells were fixed and incubated with peroxidase-conjugated anti-BrdU antibody. Then, the peroxidase substrate 3,3',5,5'-tetramethylbenzidine was added, and BrdU incorporation was quantitated by the difference in the absorbance at 370 and 492 nm.

2.7. Assessment of apoptosis by Annexin V/propidium iodide double-staining assay

Cells were incubated for 48 h with SP600125 and then collected, washed with PBS, and resuspended in Annexin V binding buffer (1×10^6 cells/ml final concentration). The amount of apoptotic cells were identified by double supravital staining with recombinant fluorescein isothiocyanate-conjugated Annexin V antibody (Dako) and propidium iodide. Flow cytometric analysis was performed immediately after the supravital staining. The data acquisition and analysis were performed in a FACSCalibur flow cytometer using CellQuest software (BD Biosciences).

2.8. siRNA transfections

MPS1 was targeted with two distinct siRNAs (Dharmacon Inc.) that were delivered into MCF7, MDA-MB-231 and T47D BC cells by oligofectamine (Invitrogen). After 48 h, the effect of silencing on protein expression levels was determined by immunoblotting. We optimized the transfection conditions for each cell lines, as previously described, with minimum modifications (Bianchini et al., 2010). Briefly, we used three different types of negative controls, including cells grown in regular OptiMEM medium (Invitrogen), cells grown in the presence of transfection reagents only, and cells transfected with control siRNA, including four different constructs and four different siRNA constructs (Dharmacon Inc.). Different positive controls (40 nmol/L final concentration) were used to define the optimal transfection efficiency conditions. Gene silencing was performed in three replicates in 96-well plates using predetermined optimal transfection conditions. The cells were seeded at a density that yielded 70–80% confluence in the control wells at 96 h. Each plate included wells with target siRNAs (40 nmol/L per well in a 50 μ L total volume) and negative and positive siRNA controls; the plates were incubated at 37 °C for 96 h.

2.9. Immunoprecipitation/kinase assay

The immunoprecipitation/kinase assay was performed as previously described (Huang et al., 2009a,b). Briefly, MCF7, MDA-MB-231 and T47D cells were lysed, and MPS1 was immunoprecipitated from the cell lysates with anti-MPS1 antibody (Acris Antibodies GmbH) and washed three times in CSK Buffer (10 mM piperazine-N,N-bis(2-ethanesulfonic acid) (pH 7.0), 100 mM NaCl, 3 mM MgCl₂, 300 mM sucrose, and 0.1% NP-40) to which 0.7 M LiCl was added for the second wash. After two washes in kinase buffer, the kinase reaction was carried out using His-TP53 as substrate. The reaction was stopped by the addition of a 0.5 volume of protein sample buffer, and the proteins were resolved by SDS-PAGE. The phosphorylation of TP53 was visualized by Western blotting using an anti-phospho-TP53 antibody (Cell Signaling).

3. Results

3.1. Identification of genes correlated with TP53 status

Five independent BC datasets containing informations on TP53 mutation status, gene expression and clinical data were used as the discovery cohort (Supplementary Table 1). We independently assessed ER-positive ($n = 511$) and ER-negative ($n = 184$) patients to identify genes associated with mutant TP53 using ROC analysis. We identified 4172 and 794 mutant TP53-associated genes in ER-positive and ER-negative groups, respectively ($p < 0.001$; Supplementary Table 2A and B). The ROC results for the top ranking genes for ER-positive and ER-negative BC patients are listed in

Table 1 – Receiver Operating Characteristic analysis in ER-positive and ER-negative breast cancer patients. * $p < 0.001$. MPS1 was the gene with the highest AUC value in ER-positive tumors.

Affymetrix ID	Gene symbol	AUC	p-value
ER-positive			
204822_at	MPS1	0.814	<1E-16*
202870_s_at	CDC20	0.804	<1E-16*
210052_s_at	TPX2	0.803	<1E-16*
204962_s_at	CENPA	0.802	<1E-16*
202705_at	CCNB2	0.790	<1E-16*
201710_at	MYBL2	0.789	<1E-16*
208079_s_at	AURKA	0.785	<1E-16*
203438_at	STC2	0.782	<1E-16*
209773_s_at	RRM2	0.781	<1E-16*
ER-negative			
201774_s_at	NCAPD2	0.779	1.29E-12*
209710_at	GATA2	0.759	2.01E-10*
201286_at	SDC1	0.729	4.96E-09*
203233_at	IL4R	0.765	1.15E-08*
203758_at	CTS0	0.759	1.28E-08*
209421_at	MSH2	0.733	5.90E-08*
219076_s_at	PXMP2	0.739	6.48E-08*
208763_s_at	TSC22D3	0.741	8.01E-08*
211623_s_at	FBL	0.759	9.26E-08*

Table 1. The top-ranked gene in ER-positive tumors, the *MPS1* kinase, was the most significant one associated with TP53 status (AUC = 0.814, $p < 1E-16$). *MPS1* remained significantly associated with TP53 status even when the individual datasets were analyzed separately (GSE3494: AUC = 0.852, $p < 1E-16$; GSE22093: AUC = 0.78, $p = 1.45E-06$; E-MTAB-43: AUC = 0.82, $p = 9.0E-04$; E-MTAB-365: AUC = 0.77, $p = 7.42E-14$). To evaluate the impact of the most significant genes associated with TP53 status we used the DAVID server. We identified specific and significantly enriched canonical signaling pathways potentially activated by mutations of TP53 ($p < 0.01$) (Supplementary Table 3). Functional annotation clustering for all the significantly

mutant TP53-associated genes in ER-positive tumors revealed “Cell cycle” ($p = 9.2E-6$), “DNA replication” ($p = 1.0E-3$), “Mismatch repair” ($p = 1.9E-3$), “TP53 signaling pathway” ($p = 2.8E-3$) and “Nucleotide excision repair” ($p = 1.3E-2$). The most relevant enriched pathways among the mutant TP53-correlated genes in the ER-negative patients were “Mismatch repair” ($p = 1.1E-6$), “DNA replication” ($p = 1.2E-6$), “Cell cycle” ($p = 1.4E-6$), “Pathways in cancer” ($p = 6.0E-3$), “Nucleotide excision repair” ($p = 7.0E-3$) and “ECM-receptor interaction” ($p = 1.1E-2$). Of note, cell cycle was the category hit by most of the genes; therefore, we used the KEGG cell cycle pathway map to visualize the genes with altered expression in TP53 mutant




Figure 2 – Survival analysis in neoadjuvant chemotherapy-treated breast cancer patients for three of the top ranking genes identified using ROC analysis. (n.s. = not significant; RFS = relapse-free survival).

cancers (Supplementary Figure 1). TP53 mutations were more frequent in ER-negative tumors (Chi-square test $p = 0.0001$).

3.2. Survival analysis in untreated breast cancer patients and patients treated with systemic chemotherapy

To evaluate the prognostic value of the genes associated with TP53 status we downloaded the expression data for 684 lymph node negative untreated patients including 553 ER-positive and 132 ER-negative patients of three independent datasets (Supplementary Table 1). In the ER-positive patients, low *MPS1* expression was associated with longer relapse-free survival (HR = 1.89, $p = 1.85E-05$, Supplementary Figure 2). In the untreated BC series, after correction for HER2 (Cox multivariate regression model), *MPS1* was still significant prognostic (HR = 1.87, $p = 3.99E-05$). *MPS1* retained its prognostic significance even after stratification for lymph node status (lymph node positive patients: HR = 2.4, $p = 4.9E-04$; lymph node negative patients: HR = 11.9, $p = 0.0022$).

We also assessed the association of these classes of genes with clinical outcome in patients treated with systemic therapy. Survival data available for 528 BC patients who received neoadjuvant chemotherapy (Supplementary Table 1) were used for further validation by employing Kaplan–Meier analysis (Figure 1). None of these validation samples was included in the discovery cohort. The Kaplan–Meier plots for three of the top genes in each cohort are depicted in Figure 2. We performed Cox regression analysis in ER-positive and ER-negative BC patients on the genes with the highest AUC values (Table 2). We found that the gene with the highest AUC value in ER-positive tumors, *MPS1*, was also strongly associated with patient relapse-free survival (HR = 2.5, $p = 4.0E-05$; Table 2). Analysis in ER-negative tumors did not reveal any gene correlated with TP53 status significantly associated with risk of relapse (Table 2 and Figure 2). In addition, to demonstrate the robustness of the median approach used in our study we randomly divided the neoadjuvant treated ER-positive cohort into two cohorts of equal size. The median expression of *MPS1* in the training cohort was used in the Cox regression analysis for both the training and the testing cohorts; the gene retained its significant association with relapse-free survival in both cohorts (Supplementary Figure 3). Pearson correlation analysis demonstrated that almost all of the top TP53-associated genes were correlated with proliferation (Supplementary Table 4).

3.3. Loss of *MPS1* results in decreased survival and induction of apoptosis in breast cancer cells

We analyzed a large BC cell line dataset (<http://www.ebi.ac.uk/arrayexpress/>, accession No. E-TABM-157) (Neve et al., 2006) and verified that *MPS1* was expressed, though at different levels, in all BC cell lines (data not shown). For *in vitro* analysis, we selected one TP53 wild-type cell line (MCF7, luminal) and two TP53-mutated BC cell lines (T47D, luminal and MDA-MB-231, basal-like). To determine the basal *MPS1* activity levels and the effect of the *MPS1* inhibitor SP600125 on BC cells, *in vitro* kinase assays were employed using *MPS1* immunoprecipitated from MCF7, T47D and MDA-MB-231 cells. The phosphorylation

Table 2 – Cox regression analyses in ER-positive and ER-negative breast cancer patients performed on the genes ranked by the highest AUC values. * $p < 0.001$. *MPS1* was the most significant gene associated with poor outcome in ER-positive tumors.

Affymetrix ID	Gene symbol	HR	p -value
ER-positive			
204822_at	<i>MPS1</i>	2.5	4.0E-05*
202870_s_at	<i>CDC20</i>	2.1	1.2E-03
210052_s_at	<i>TPX2</i>	1.47	0.08
204962_s_at	<i>CENPA</i>	2.1	1.3E-03
202705_at	<i>CCNB2</i>	2.2	3.7E-04*
201710_at	<i>MYBL2</i>	1.31	0.22
208079_s_at	<i>AURKA</i>	2.2	3.9E-04*
203438_at	<i>STC2</i>	0.32	7.0E-07*
209773_s_at	<i>RRM2</i>	2.3	2.9E-04*
ER-negative			
201774_s_at	<i>NCAPD2</i>	1.14	0.56
209710_at	<i>GATA2</i>	1.30	0.23
201286_at	<i>SDC1</i>	1.02	0.94
203233_at	<i>IL4R</i>	1.20	0.41
203758_at	<i>CTSO</i>	0.73	0.16
209421_at	<i>MSH2</i>	0.82	0.36
219076_s_at	<i>PXMP2</i>	0.86	0.5
208763_s_at	<i>TSC22D3</i>	0.84	0.43
211623_s_at	<i>FBL</i>	0.88	0.54

of TP53, a downstream target of *MPS1*, at threonine-18 was assessed by Western blotting. As shown in Figure 3, *MPS1* activity was detected in all BC cell lines and was found to be consistently elevated in T47D cells. Furthermore, SP600125 at 10 μ M significantly reduced the *MPS1* activity in all BC cells (Figure 3), confirming *MPS1* as a specific target of SP600125.

Reduction in *MPS1* levels has been found to decrease the viability of several human cancer cell lines (Janssen et al., 2009). To explore the role of *MPS1* in BC cells, we examined the effect of *MPS1* gene silencing in MCF7, MDA-MB-231 and T47D cell lines. Treatment with *MPS1*-siRNA resulted in a reduced expression of the *MPS1* protein in all of the cell lines tested (Figure 4A), whereas control cells and non-targeting siRNA transfected cells retained normal *MPS1* protein




Figure 3 – *MPS1* activity and the effect of SP600125 (*MPS1i*) in breast cancer cell lines. Immunoprecipitated endogenous *MPS1* phosphorylated TP53 on Thr18. Immunoprecipitation/kinase assays were performed using *MPS1* immunoprecipitated from MCF7, T47D and MDA-MB-231 cells. Normal rabbit immunoglobulin G was used as control. Phosphorylation of the substrate (His-TP53) was detected by Western blotting using an anti-phospho-Thr18-TP53 antibody.

expression (Figure 4A), confirming the *MPS1* silencing efficiency of the *MPS1*-siRNA. The cell viability and cell proliferation were then assessed by the MTT assay (Figure 4B) and BrdU incorporation (Figure 4C), respectively. We found that *MPS1* silencing had no effect on the proliferative potential of MCF7 and a slight effect ($p < 0.05$) on cell viability and proliferation in both of the *TP53*-mutant cell lines. This result indicates that the *TP53*-mutated BC cells and *TP53* wild-type MCF7 cells have differential requirements for *MPS1*, potentially corresponding to their *TP53* functional status.

Similar results were obtained with the *MPS1* inhibitor SP600125 (Figure 5A). Inhibition of *MPS1* was not sufficient to consistently reduce the viability of MCF7 cells and showed only marginal effects ($p < 0.05$) on the viability of the *TP53*-mutated BC cell lines (Figure 5A). In the presence of the *MPS1* inhibitor, the *TP53* wild-type MCF7 cells did not manifest any increased staining for Annexin V (Figure 5B). Conversely, both *TP53*-mutated BC cell lines showed a markedly increased rate of apoptosis (Figure 5B), consistent with the concept that a reduction in *MPS1* causes cellular apoptosis rather than simply a reduction in cell growth rates. Furthermore, *MPS1*

inhibition was more efficient ($p < 0.01$) in increasing apoptosis in ER-positive T47D cells compared with ER-negative MDA-MB-231 cells ($p < 0.05$). These results, in line with the *in silico* analyses, establish that *MPS1* inhibition preferentially impaired *TP53*-mutated cells, and that *MPS1* is a potential therapeutic target for *TP53*-mutated ER-positive breast cancers.

To further assess the potential therapeutic value of *MPS1* inhibition in combined therapy, we analyzed the effect of SP600125 in combination with conventional chemotherapeutic drugs in different BC cell lines (Figure 6). SP600125 alone consistently reduced *TP53*-mutated cells survival ($p < 0.05$), but had no significant effects on MCF7 survival (Figure 6). Of note, *MPS1* inhibition had a synergistic effect on cell survival in mutant *TP53* cells either in combination with doxorubicin ($p < 0.01$), or with paclitaxel ($p < 0.001$). Although the combination with taxanes and anthracyclines caused a decrease of cell survival also in MCF7 ($p < 0.05$), the observed synergistic effect was negligible with respect to *TP53*-mutated cells, suggesting that this type of cells is sensitive at less extent to the inhibition of *MPS1* (Figure 6).




Figure 4 – Viability and proliferation of breast cancer cells after the reduction of *MPS1* expression levels with siRNA. (A) Western blot analysis showing protein levels of parental control (transfection reagents only), non-targeting construct-transfected, and *MPS1* siRNA-transfected after 48 h. Cell viability (B) and cell proliferation (C) after silencing of *MPS1* were determined by MTT assay and BrdU incorporation, respectively. Error bars represent the S.D. of triplicate measurements. # $p < 0.05$.




Figure 5 – Effects of SP600125 (MSP1i) on viability and apoptosis in breast cancer cell lines. MCF7, T47D and MDA-MB-231 cells were treated with 10 μ M SP600125 or DMSO alone (control) for 72 h. (A) Cell viability was analyzed by MTT assay. (B) Apoptotic cells were detected by propidium iodide and Annexin V staining. Histogram comparing the percent of apoptotic cells in each of the different treatments are shown. Error bars represent the S.D. of triplicate measurements. # $p < 0.05$, * $p < 0.01$.

4. Discussion

TP53 is an important prognostic indicator in BC, and dysfunctions of this gene have been demonstrated to affect different gene patterns. Moreover, BC with TP53 mutations tend to have fewer mutations in other driver cancer genes, suggesting

a crucial role of the TP53 signaling pathway in these cancer cells ([Cancer Genome Atlas Network, 2012](#)).

In this study, we assembled several different BC datasets to assess the effect of TP53 status on the potential regulation of specific genes, to evaluate their prognostic value, and identify genes to target in TP53 mutated ER-positive and ER-negative BC subtypes. We established two distinct sets of genes




Figure 6 – Effects of SP600125 (SP) in combination with taxane (tax) or anthracycline (dox) on breast cancer cells survival assessed by MTT assay. MCF7, T47D and MDA-MB-231 cells were treated with 10 μ M SP alone or in combination with paclitaxel (1 μ M) or doxorubicin (4 μ M). Error bars indicate the S.D. ($n = 3$). # $p < 0.05$, * $p < 0.01$, ** $p < 0.001$.

associated with TP53 status in ER-positive and ER-negative BCs and demonstrated that single genes were able to predict TP53 dysfunction in both subtypes. This suggests a potential intersection in the activation of transcriptional programs regulated by TP53 in both cancer groups. However, genes correlated with mutant TP53 were associated with relapse-free survival only in ER-positive tumors, suggesting that the expression of some genes in TP53 mutated tumors may be dependent on ER status. The prognostic genes associated with TP53 status and identified in the discovery dataset were confirmed in a large cohort of lymph-node negative untreated BC patients.

The prognostic value of the two sets of genes was confirmed in ER-positive and ER-negative BC patients treated with neoadjuvant chemotherapies, including taxane-anthracycline based regimens. The genes associated with TP53 status were confirmed to be prognostic only in ER-positive tumors and independently from the type of chemotherapy received. The same analysis performed for TP53-genes on the ER-negative group had no consistent prognostic value. Some of the genes associated with TP53 status are also linked to cell cycle and proliferation, making the latter a potential confounding variable in the identification of prognostic biomarker. However, important studies have demonstrated that despite TP53 mutations are directly linked to high tumor proliferation rates, both factors remain independently associated with BC prognosis (Allred et al., 1993; Yerushalmi et al., 2010). In our results, as expected, we found that numerous top-ranked genes linked to TP53 status were also significantly associated with proliferation and tumor relapse. To make our approach reliable and robust, from our data we selected MPS1 (also named TTK), the gene with the highest AUC value linked with TP53 status, and most significantly associated with poor prognosis. MPS1 was previously included in different prognostic proliferation-based signatures (Sotiriou et al., 2006; Bianchini et al., 2010), and in a 16-kinase signature that was able to further distinguish two subgroups of luminal A tumors with different survival (Finetti et al., 2008). In spite of the strong link between MPS1 and proliferation, this kinase has also recently been established as part of a gene module dependent on TP53 status, which further stratified luminal tumors, independently of proliferation. These observations shed light on the biological consequences of specific defective cell cycle checkpoints upon regulation of TP53-modulated kinase genes, such as MPS1, in this subgroup of luminal tumors, which are most likely characterized by higher genomic instability (Fredlund et al., 2012). These findings indirectly support the correctness of the approach and gene selection adopted in our study, and suggest that this poor prognosis luminal subgroup could be enriched for distinct genomically unstable TP53-mutated tumors.

These observations also suggest that TP53 mutations may activate specific transcriptional checkpoint programs that in turn could destabilize the interactions between TP53 and ER thus explaining the resistance of specific ER-positive tumors to apoptosis (Bailey et al., 2012). Accordingly, in our study, the top-scored genes associated with TP53 status in ER-positive tumors were enriched for functions related to mitotic spindle assembly and checkpoint regulation (MPS1, CDC20, TPX2, CCNB2, and AURKA). Our data are also in agreement with a recent study demonstrating that a subset of poor

prognostic luminal tumors was linked to TP53-regulated programs, and genomic instability (Ciriello et al., 2013).

TP53 is capable to regulate a number of checkpoint and mitotic kinases; few of these have been recently investigated as potential targets for therapies (Ha and Breuer, 2012). The MPS1 gene encodes for a dual serine/threonine kinase, which is involved in the mitotic spindle assembly checkpoint (SAC) (Jones et al., 2005; Weiss and Winey, 1996), chromosome stability (Leng et al., 2006), DNA damage checkpoints (Wei et al., 2005) and the TP53-dependent mitotic checkpoint (Huang et al., 2009c). In this study, the prognostic value of MPS1 in BC was confirmed in both ER-positive untreated patients, and in ER-positive patients treated with neoadjuvant chemotherapy. MPS1 was prognostic after stratification for lymph node status, and as TP53 status, independently from the type of therapy administered (Bonnetfoi et al., 2011). Our *in vitro* results paralleled and supported the *in silico* data, suggesting that MPS1 is a potential TP53-regulated kinase to target in BC. Accordingly, in our study, the inhibition of MPS1 by siRNA and a chemical inhibitor, strengthened the important role played by this kinase in a subset of TP53-mutated ER-positive tumors characterized by poor prognosis. We demonstrated that all BC cell lines expressed MPS1 and that the loss of MPS1 resulted in decreased cell viability and proliferation. The TP53-mutated (MDA-MB-231 and T47D) and TP53 wild-type (MCF7) BC cells had differential requirements for MPS1, potentially corresponding to their different TP53 functional status. The potent biological activity of SP600125, a small pan-kinase mitotic inhibitor, demonstrated that the inhibition of MPS1 resulted in decreased cell viability and induction of apoptosis in BC cell lines with dysfunctions of TP53. MPS1, regulates checkpoint activity that is selectively required to sustain the proliferation of aneuploid tumors, and it is associated with chromosomal instability in different cancer types (Carter et al., 2006; Daniel et al., 2011). Our data suggest that the checkpoint inactivation leading to aneuploidy may serve as a mechanism by which MPS1 inhibition causes the loss of cell viability and the induction of apoptosis in mutated BC cells. In line with our findings, MPS1 has recently been suggested as a potential target for tumors characterized by high genomic instability, such as melanomas mutated for BRAF-V600E (Liu et al., 2013), basal-like BC (Maire et al., 2013), and glioblastomas (Tannous et al., 2013).

In this study, we confirmed a significant high activity of SP600125 in TP53 mutated BC cell lines, which are known to be characterized by high genomic instability and aneuploidy. Additional studies using these classes of anti-checkpoint/mitotic inhibitors in these types of cancer cells support the consistency of our findings (Colombo et al., 2010).

Our data also proved that SP600125 added to cytotoxic drugs has an important effect on cell survival, enhancing the sensitivity of BC cells to chemotherapy, particularly to anti-tubulin drugs. Comparable results were reported on recent different studies, which showed that MPS1 depletion was highly toxic in cancer cell lines if added in combination with chemotherapy (Janssen et al., 2009; Jemaà et al., 2013). TP53-incompetent cells can override mitotic checkpoints becoming aneuploid, and contributing to chromosomal instability and resistance to therapy (Weaver and Cleveland, 2005; Cheok et al., 2011; Murray et al., 2012).

Consequently, it will be important to select compounds that preferentially kill TP53-incompetent cells (Brown et al., 2009). Accordingly, SP600125 could selectively target TP53-mutated proliferating mitotic cells in tumors, enhancing cell sensitivity to current chemotherapeutic drugs. Moreover, SP600125 may exert these cytotoxic effects through the concurrent inhibition of few serine/threonine kinases; although, the inhibition of MPS1 appears to be co-responsible for the preferential effects of SP600125 on the cell cycle of TP53^{-/-} cells (Jemaà et al., 2012; Brown et al., 2009). Accordingly, we have demonstrated that SP600125 kills TP53-defective cells more efficiently than their TP53-proficient counterparts *in vitro*. Our data also suggest that mitotic associated checkpoint drugs including, SP600125 (or other drugs with “similar” activity, such as, NMS-P715, MPI-0479605, AZ3146 etc.), could be suitable candidates for further development toward clinical studies in genomically unstable breast tumors.

In conclusion, altogether our data demonstrate that TP53 status is associated with important key mitotic-checkpoint kinases, such as MPS1, involved in tumor relapse in a specific subset of ER-positive tumors. MPS1 is predominantly expressed and activated by the loss of function mutations of TP53 in human breast tumors, and the inhibition of this marker efficiently increases the apoptosis of TP53 defective BC cell lines, particularly those expressing the estrogen receptor. Finally, the concurrent inhibition of important kinases, including MPS1, by SP600125 could have a synergistic cellular proapoptotic effect, which may be exploited for the therapeutic advantage of increasing cancer cell toxicities.

Acknowledgements

This study was supported by the OTKA PD 83154 Grant (to B.G.), the Predict project (Grant no. 259303 of the EU Health.2010.2.4.1.-8 call to B.G.), Associazione Italiana per la Ricerca sul Cancro (AIRC Grant-6251 to L.S.).

Appendix A. Supplementary data

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.molonc.2013.12.018>

REFERENCES

- Allred, D.C., Clark, G.M., Elledge, R., Fuqua, S.A., Brown, R.W., Chamness, G.C., Osborne, C.K., McGuire, W.L., 1993. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. *J. Natl. Cancer Inst.* 85, 200–206.
- Bailey, S.T., Shin, H., Westerling, T., Liu, X.S., Brown, M., 2012. Estrogen receptor prevents p53-dependent apoptosis in breast cancer. *Proc. Natl. Acad. Sci. U S A* 109, 18060–18065.
- Bertheau, P., Turpin, E., Rickman, D.S., Espié, M., de Reyniès, A., Feugeas, J.P., Plassa, L.F., Soliman, H., Varna, M., de Roquancourt, A., Lehmann-Che, J., Beuzard, Y., Marty, M., Misset, J.L., Janin, A., de Thé, H., 2007. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. *PLoS. Med.* 4, e90.
- Bianchini, G., Iwamoto, T., Qi, Y., Coutant, C., Shiang, C.Y., Wang, B., Santarpia, L., Valero, V., Hortobagyi, G.N., Symmans, W.F., Gianni, L., Pusztai, L., 2010. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. *Cancer Res.* 70, 8852–8862.
- Bonnefoi, H., Piccart, M., Bogaerts, J., Mauriac, L., Fumoleau, P., Brain, E., Petit, T., Rouanet, P., Jassem, J., Blot, E., Zaman, K., Cufer, T., Lortholary, A., Lidbrink, E., André, S., Litière, S., Lago, L.D., Becette, V., Cameron, D.A., Bergh, J., Iggo, R.EORTC 10994/BIG 1-00 Study Investigators, 2011. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. *Lancet Oncol.* 12, 527–539.
- Brown, C.J., Lain, S., Verma, C.S., Fersht, A.R., Lane, D.P., 2009. Awakening guardian angels: drugging the p53 pathway. *Nat. Rev. Cancer* 9, 862–873.
- Cancer Genome Atlas Network, 2012. Comprehensive molecular portraits of human breast tumors. *Nature* 490, 61–70.
- Carter, S.L., Eklund, A.C., Kohane, I.S., Harris, L.N., Szallasi, Z., 2006. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. *Nat. Genet.* 38, 104–1048.
- Cheok, C.F., Verma, C.S., Baselga, J., Lane, D.P., 2011. Translating p53 into the clinic. *Nat. Rev. Clin. Oncol.* 8, 25–37.
- Ciriello, G., Sinha, R., Hoadley, K.A., Jacobsen, A.S., Reva, B., Perou, C.M., Sander, C., Schultz, N., 2013. The molecular diversity of Luminal A breast tumors. *Breast Cancer Res. Treat* 141, 409–420.
- Colombo, R., Caldarelli, M., Mennecozzi, M., Giorgini, M.L., Sola, F., Cappella, P., Perrera, C., Depaolini, S.R., Rusconi, L., Cucchi, U., Avanzi, N., Bertrand, J.A., Bossi, R.T., Pesenti, E., Galvani, A., Isacchi, A., Colotta, F., Donati, D., Moll, J., 2010. Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. *Cancer Res.* 70, 10255–10264.
- Coutant, C., Rouzier, R., Qi, Y., Lehmann-Che, J., Bianchini, G., Iwamoto, T., Hortobagyi, G.N., Symmans, W.F., Uzan, S., Andre, F., de Thé, H., Pusztai, L., 2011. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. *Clin. Cancer Res.* 17, 2591–2601.
- Daniel, J., Coulter, J., Woo, J.H., Wilsbach, K., Gabrielson, E., 2011. High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells. *Proc. Natl. Acad. Sci. U S A* 108, 5384–5389.
- Desmedt, C., Giobbie-Hurder, A., Neven, P., Paridaens, R., Christiaens, M.R., Smeets, A., Lallemand, F., Haibe-Kains, B., Viale, G., Gelber, R.D., Piccart, M., Sotiriou, C., 2009. The gene expression grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. *BMC. Med. Genomics* 2, 40.
- Desmedt, C., Di Leo, A., de Azambuja, E., Larsimont, D., Haibe-Kains, B., Selleslags, J., Delalogue, S., Duhem, C., Kains, J.P., Carly, B., Maerevoet, M., Vindevoghel, A., Rouas, G., Lallemand, F., Durbecq, V., Cardoso, F., Salgado, R., Rovere, R., Bontempi, G., Michiels, S., Buyse, M., Nogaret, J.M., Qi, Y., Symmans, F., Pusztai, L., D'Hondt, V., Piccart-Gebhart, M., Sotiriou, C., 2011. Multifactorial approach to predicting resistance to anthracyclines. *J. Clin. Oncol.* 29, 1578–1586.
- Finetti, P., Cervera, N., Charafe-Jauffret, E., Chabannon, C., Charpin, C., Chaffanet, M., Jacquemier, J., Viens, P., Birnbaum, D., Bertucci, F., 2008. Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. *Cancer Res.* 68, 767–776.
- Fredlund, E., Staaf, J., Rantala, J.K., Kallioniemi, O., Borg, A., Ringnér, M., 2012. The gene expression landscape of breast

- cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. *Breast Cancer Res.* 14, R113.
- Gyorffy, B., Benke, Z., Lániczky, A., Balázs, B., Szállási, Z., Timár, J., Schäfer, R., 2012. Recurrence online: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. *Breast Cancer Res. Treat.* 132, 1025–1034.
- Gyorffy, B., Lániczky, A., Eklund, A.C., Denkert, C., Budczies, J., Li, Q., Szallasi, Z., 2010. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. *Breast Cancer Res. Treat.* 123, 725–731.
- Gyorffy, B., Molnar, B., Lage, H., Szallasi, Z., Eklund, A.C., 2009. Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples. *PLoS. One* 4, e5645.
- Gyorffy, B., Schäfer, R., 2009. Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients. *Breast Cancer Res. Treat.* 118, 433–441.
- Ha, G.H., Breuer, E.K., 2012. Mitotic kinases and p53 signaling. *Biochem. Res. Int.* 2012, 195903.
- Hatzis, C., Pusztai, L., Valero, V., Booser, D.J., Esserman, L., Lluch, A., Vidaurre, T., Holmes, F., Souchon, E., Wang, H., Martin, M., Cotrina, J., Gomez, H., Hubbard, R., Chacón, J.I., Ferrer-Lozano, J., Dyer, R., Buxton, M., Gong, Y., Wu, Y., Ibrahim, N., Andreopoulou, E., Ueno, N.T., Hunt, K., Yang, W., Nazario, A., DeMichele, A., O'Shaughnessy, J., Hortobagyi, G.N., Symmans, W.F., 2011. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. *JAMA* 305, 1873–1881.
- Huang, D.W., Sherman, B.T., Lempicki, R.A., 2009a. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* 4, 44–57.
- Huang, D.W., Sherman, B.T., Lempicki, R.A., 2009b. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res.* 37, 1–13.
- Huang, Y.F., Chang, M.D., Shieh, S.Y., 2009c. TTK/hMps1 mediates the p53-dependent postmitotic checkpoint by phosphorylating p53 at Thr18. *Mol. Cell. Biol.* 29, 2935–2944.
- Iwamoto, T., Bianchini, G., Booser, D., Qi, Y., Coutant, C., Shiang, C.Y., Santarpia, L., Matsuoka, J., Hortobagyi, G.N., Symmans, W.F., Holmes, F.A., O'Shaughnessy, J., Hellerstedt, B., Pippen, J., Andre, F., Simon, R., Pusztai, L., 2011. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. *J. Natl. Cancer Inst.* 103, 264–272.
- Janssen, A., Kops, G.J., Medema, R.H., 2009. Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. *Proc. Natl. Acad. Sci. U S A* 106, 19108–19113.
- Jemaà, M., Galluzzi, L., Kepp, O., Senovilla, L., Brands, M., Boemer, U., Koppitz, M., Lienau, P., Prechtel, S., Schulze, V., Siemeister, G., Wengner, A.M., Mumberg, D., Ziegelbauer, K., Abrieu, A., Castedo, M., Vitale, I., Kroemer, G., 2013. Characterization of novel MPS1 inhibitors with preclinical anticancer activity. *Cell. Death Differ.*
- Jemaà, M., Vitale, I., Kepp, O., Berardinelli, F., Galluzzi, L., Senovilla, L., Mariño, G., Malik, S.A., Rello-Varona, S., Lissa, D., Antocchia, A., Tailler, M., Schlemmer, F., Harper, F., Pierron, G., Castedo, M., Kroemer, G., 2012. Selective killing of p53-deficient cancer cells by SP600125. *EMBO. Mol. Med.* 4, 500–514.
- Jones, M.H., Huneycutt, B.J., Pearson, C.G., Zhang, C., Morgan, G., Shokat, K., Bloom, K., Winey, M., 2005. Chemical genetics reveals a role for Mps1 kinase in kinetochore attachment during mitosis. *Curr. Biol.* 15, 160–165.
- Kanehisa, M., Goto, S., 2000. KEGG: Kyoto encyclopedia of genes and genomes. *Nucleic Acids Res.* 28, 27–30.
- Karn, T., Pusztai, L., Holtrich, U., Iwamoto, T., Shiang, C.Y., Schmidt, M., Müller, V., Solbach, C., Gaetje, R., Hanker, L., Ahr, A., Liedtke, C., Ruckhäberle, E., Kaufmann, M., Rody, A., 2011. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. *PLoS. One* 6, e28403.
- Kim, M., Wiemer, D.F., 2004. EDC-mediated condensations of 1-chloro-5-hydrazino-9,10-anthracenedione, 1-hydrazino-9,10-anthracenedione, and the corresponding anthrapyrazoles. *Tetrahedron Lett.* 45, 4977–4980.
- Leng, M., Chan, D.W., Luo, H., Zhu, C., Qin, J., Wang, Y., 2006. MPS1-dependent mitotic BLM phosphorylation is important for chromosome stability. *Proc. Natl. Acad. Sci. U S A* 103, 11485–11490.
- Li, Q., Birkbak, N.J., Gyorffy, B., Szallasi, Z., Eklund, A.C., 2011. Jets: selecting the optimal microarray probe set to represent a gene. *BMC. Bioinfo.* 12, 474.
- Liu, J., Cheng, X., Zhang, Y., Li, S., Cui, H., Zhang, L., Shi, R., Zhao, Z., He, C., Wang, C., Zhao, H., Zhang, C., Fisk, H.A., Guadagno, T.M., Cui, Y., 2013. Phosphorylation of Mps1 by BRAFV600E prevents Mps1 degradation and contributes to chromosome instability in melanoma. *Oncogene* 32, 713–723.
- Maire, V., Baldeyron, C., Richardson, M., Tesson, B., Vincent-Salomon, A., Gravier, E., Marty-Prouvost, B., De Koning, L., Rigail, G., Dumont, A., Gentien, D., Barillot, E., Roman-Roman, S., Depil, S., Cruzalegui, F., Pierré, A., Tucker, G.C., Dubois, T., 2013. TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. *PLoS. One* 8, e63712.
- Miller, L.D., Smeds, J., George, J., Vega, V.B., Vergara, L., Ploner, A., Pawitan, Y., Hall, P., Klaar, S., Liu, E.T., Bergh, J., 2005. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. *Proc. Natl. Acad. Sci. U S A* 102, 13550–13555.
- Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. *Open. Med.* 3, e123–130.
- Murray, S., Briasoulis, E., Linardou, H., Bafaloukos, D., Papadimitriou, C., 2012. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. *Cancer Treat. Rev.* 38, 890–903.
- Neve, R.M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F.L., Fevr, T., Clark, L., Bayani, N., Coppe, J.P., Tong, F., Speed, T., Stillman, P.T., DeVries, S., Lapuk, A., Wang, N.J., Kuo, W.L., Stilwell, J.L., Pinkel, D., Albertson, D.G., Waldman, F.M., McCormick, F., Dickson, R.B., Johnson, M.D., Lippman, M., Ethier, S., Gazdar, A., Gray, J.W., 2006. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. *Cancer Cell.* 10, 515–527.
- Olivier, M., Langerød, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J., Theillet, C., Rodriguez, C., Lidereau, R., Bièche, I., Varley, J., Bignon, Y., Uhrhammer, N., Winqvist, R., Jukkola-Vuorinen, A., Niederacher, D., Kato, S., Ishioka, C., Hainaut, P., Børresen-Dale, A.L., 2006. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. *Clin. Cancer Res.* 12, 1157–1167.
- Reme, T., Hose, D., Theillet, C., Klein, B., 2013. Modeling risk stratification in human cancer. *Bioinformatics* 29, 1149–1157.
- Santarpia, L., Iwamoto, T., Di Leo, A., Hayashi, N., Bottai, G., Stampfer, M., Andre, F., Turner, N.C., Symmans, W.F., Hortobagyi, G.N., Pusztai, L., Bianchini, G., 2013. DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. *Oncologist* 18, 1063–1073.
- Santarpia, L., Qi, Y., Stemke-Hale, K., Wang, B., Young, E.J., Booser, D.J., Holmes, F.A., O'Shaughnessy, J., Hellerstedt, B., Pippen, J., Vidaurre, T., Gomez, H., Valero, V., Hortobagyi, G.N., Symmans, W.F., Bottai, G., Di Leo, A., Gonzalez-Angulo, A.M., Pusztai, L., 2012. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. *Breast Cancer Res. Treat.* 13, 333–343.

- Sotiriou, C., Pusztai, L., 2009. Gene-expression signatures in breast cancer. *N. Engl. J. Med.* 360, 790–800.
- Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S., Smeds, J., Nordgren, H., Farmer, P., Praz, V., Haibe-Kains, B., Desmedt, C., Larsimont, D., Cardoso, F., Peterse, H., Nuyten, D., Buyse, M., Van de Vijver, M.J., Bergh, J., Piccart, M., Delorenzi, M., 2006. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. *J. Natl. Cancer Inst.* 98, 262–272.
- Tannous, B.A., Kerami, M., Van der Stoop, P.M., Kwiatkowski, N., Wang, J., Zhou, W., Kessler, A.F., Lewandrowski, G., Hiddingh, L., Sol, N., Lagerweij, T., Wedekind, L., Niers, J.M., Barazas, M., Nilsson, R.J., Geerts, D., De Witt Hamer, P.C., Hagemann, C., Vandertop, W.P., Van Tellingen, O., Noske, D.P., Gray, N.S., Würdinger, T., 2013. Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimetabolic drugs. *J. Natl. Cancer Inst.* 105, 1322–1331.
- Troester, M.A., Herschkowitz, J.I., Oh, D.S., He, X., Hoadley, K.A., Barbier, C.S., Perou, C.M., 2006. Gene expression patterns associated with p53 status in breast cancer. *BMC. Cancer* 6, 276.
- Turner, N., Moretti, E., Siclari, O., Migliaccio, I., Santarpia, L., D'Incalci, M., Piccolo, S., Veronesi, A., Zambelli, A., Del Sal, G., Di Leo, A., 2013. Targeting triple negative breast cancer: is p53 the answer? *Cancer Treat. Rev.* 39, 541–550.
- Walerych, D., Napoli, M., Collavin, L., Del Sal, G., 2012. The rebel angel: mutant p53 as the driving oncogene in breast cancer. *Carcinogenesis* 33, 2007–2017.
- Weaver, B.A., Cleveland, D.W., 2005. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. *Cancer Cell.* 8, 7–12.
- Wei, J.H., Chou, Y.F., Ou, Y.H., Yeh, Y.H., Tyan, S.W., Sun, T.P., Shen, C.Y., Shieh, S.Y., 2005. TTK/hMps1 participates in the regulation of DNA damage checkpoint response by phosphorylating CHK2 on threonine 68. *J. Biol. Chem.* 280, 7748–7757.
- Weiss, E., Winey, M., 1996. The *Saccharomyces cerevisiae* spindle pole body duplication gene MPS1 is part of a mitotic checkpoint. *J. Cell. Biol.* 132, 111–123.
- Yerushalmi, R., Woods, R., Ravdin, P.M., Hayes, M.M., Gelmon, K.A., 2010. Ki67 in breast cancer: prognostic and predictive potential. *Lancet Oncol.* 11, 174–183.